| Autor: |
Diez‐Feijóo, R., Lafuente, M., Garcia‐Gisbert, N., Fernández‐Rodríguez, C., Pinzón, S., Sánchez‐González, B., Gibert, J., Fernández‐Ibarrondo, L., Camacho, L., Longarón, R., Colomo, L., Ferrer del Álamo, A., Salido, M., Bellosillo, B., Salar, A. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p323-324, 2p |
| Abstrakt: |
When comparing SMZL and MZ-CBL, I KLF2 i mutations defined SMZL over MZ-CBL (9/33 vs. 0/16, I p i < 0.05). B Methods: b 98 patients were identified between 2014 and 2022 (33 SMZL, 32 EMZL, 6 NMZL, 16 monoclonal non-CLL B cell lymphocytosis (MZ-CBL) and 11 unclassified B-cell lymphoproliferative syndromes (LPS-NOS) with MZL clinico-biological features). B Introduction: b Marginal zone lymphoma (MZL) is a group of non-Hodgkin lymphomas that originate from the marginal zone of lymphoid follicles. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text